Shares of MAP Pharmaceuticals (UNKNOWN:MAPP.DL) skyrocketed today, up nearly 60% on the news that the company was being acquired by its marketing partner Allergan (UNKNOWN:AGN.DL) for the premium of $25 per share. In this video, Motley Fool health-care analyst David Williamson tells us some of the unexpected synergies that Allergan, the company behind Botox, will be looking for in MAP Pharmaceuticals, and why this might be a good fit.